 Connection
Rohit Katial to Anti-Asthmatic Agents
This is a "connection" page, showing publications Rohit Katial has written about Anti-Asthmatic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.381 |
|
|
|
-
Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. A Response to: Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab". Adv Ther. 2022 08; 39(8):3862-3865.
Score: 0.652
-
Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther. 2022 05; 39(5):2065-2084.
Score: 0.640
-
Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, Jacobs JS, Kraft M, Martin RJ, Nair P, Wechsler ME. Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. J Allergy Clin Immunol Pract. 2017 Mar - Apr; 5(2S):S1-S14.
Score: 0.449
-
Katial RK. A renewed focus on safety, efficacy, and use of inhaled corticosteroids in asthma. Ann Allergy Asthma Immunol. 2016 12; 117(6):575-576.
Score: 0.444
-
Katial RK, Oppenheimer JJ, Ostrom NK, Mosnaim GS, Yancey SW, Waitkus-Edwards KR, Prillaman BA, Ortega HG. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Allergy Asthma Proc. 2010 Jan-Feb; 31(1):68-75.
Score: 0.275
-
Bleecker ER, Meyers DA, Billheimer D, Li H, Newbold P, Kwiatek J, Hirsch I, Katial R, Li X. Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma. J Allergy Clin Immunol Pract. 2023 06; 11(6):1805-1813.
Score: 0.171
-
Chung Y, Katial R, Mu F, Cook EE, Young J, Yang D, Betts KA, Carstens DD. Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study. Ann Allergy Asthma Immunol. 2022 06; 128(6):669-676.e6.
Score: 0.160
-
Menzies-Gow A, Kreindler J, Katial R, Gurnell M. Adrenal insufficiency in patients taking benralizumab as corticosteroid sparing therapy - Authors' reply. Lancet Respir Med. 2022 01; 10(1):e8.
Score: 0.156
-
Virchow JC, Katial R, Brusselle GG, Shalit Y, Garin M, McDonald M, Castro M. Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials. J Allergy Clin Immunol Pract. 2020 02; 8(2):540-548.e1.
Score: 0.134
-
Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, Bateman ED, Hoyte FCL, Germinaro M. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2019 02; 7(2):589-596.e3.
Score: 0.125
-
Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013 Nov; 132(5):1086-1096.e5.
Score: 0.088
-
Katial R, Stewart L. Exhaled nitric oxide: a test for diagnosis and control of asthma? Curr Allergy Asthma Rep. 2007 Nov; 7(6):459-63.
Score: 0.059
-
Chipps BE, Corren J, Israel E, Katial R, Lang DM, Panettieri RA, Peters SP, Farrar JR. Asthma Yardstick: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma. Ann Allergy Asthma Immunol. 2017 02; 118(2):133-142.e3.
Score: 0.028
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|